Bridgeway Capital Management’s Acrivon Therapeutics ACRV Stock Holding History

Bridgeway Capital Management’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$674K	Buy	378,900 +220,000	+138%	+$374K	0.01%	797
2026 Q1	$221K	Buy	158,900 +116,000	+270%	+$202K	﹤0.01%	1015
2025 Q4	$103K	Buy	42,900 +20,000	+87%	+$43.5K	﹤0.01%	1123
2025 Q3	$41.4K	Hold	22,900	–	–	﹤0.01%	1174
2025 Q2	$27.3K	Sell	22,900 -55,000	-71%	-$75.5K	﹤0.01%	1155
2025 Q1	$158K	Buy	77,900 +3,300	+4%	+$17.8K	﹤0.01%	966
2024 Q4	$449K	Sell	74,600 -2,381	-3%	-$17.3K	0.01%	841
2024 Q3	$539K	Buy	76,981 +18,800	+32%	+$148K	0.01%	846
2024 Q2	$337K	Hold	58,181	–	–	0.01%	948
2024 Q1	$416K	Buy	58,181 +26,200	+82%	+$122K	0.01%	969
2023 Q4	$157K	Buy	+31,981	New	+$169K	﹤0.01%	1180

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bridgeway Capital Management's ACRV Position: Q2 2026 in Review

Bridgeway Capital Management increased its Acrivon Therapeutics (ACRV) stake by 138% in Q2 2026, buying an estimated $374K and bringing the position to 378,900 shares worth $674K. The position accounts for 0.01% of the portfolio, ranked #797.

Bridgeway Capital Management first reported a position in ACRV in Q4 2023 and has held it in 11 quarters since. 46 funds tracked by Wall St. Rank hold ACRV as of Q2 2026.

Bridgeway Capital Management held 378,900 shares of Acrivon Therapeutics worth $674K as of Q2 2026.
Bridgeway Capital Management bought 220,000 Acrivon Therapeutics shares in Q2 2026, an estimated $374K.
Acrivon Therapeutics made up 0.01% of Bridgeway Capital Management's portfolio in Q2 2026, its #797 holding.
Bridgeway Capital Management first reported a position in Acrivon Therapeutics in Q4 2023 and has held it in 11 quarters since.
46 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.